Upcycling umbilical cords: bridging regenerative medicine with neonatology

Alvaro G Moreira, Yasmeen Alayli, Saloni Balgi, Caitlyn Winter, Samuel Kahlenberg, Shamimunisa B Mustafa, Peter J Hornsby

Research output: Contribution to journalReview article

Abstract

Preterm birth is a major health concern that affects 10% of all worldwide deliveries. Many preterm infants are discharged from the hospital with morbidities that lead to an increased risk for neurodevelopmental impairment, recurrent hospitalizations, and life-long conditions. Unfortunately, the treatment of these conditions is palliative rather than curative, which calls for novel and innovative strategies. Progress in regenerative medicine has offered therapeutic options for many of these conditions. Specifically, human umbilical cord mesenchymal stem cells (MSCs) and cord blood (UCB) cells have shown promise in treating adult-onset diseases. Unlike bone-marrow and embryonic derived stem cells, umbilical cord-derived cells are easily and humanely obtained, have low immunogenicity, and offer the potential of autologous therapy. While there are several studies to uphold the efficacy of umbilical cord MSCs in adult therapies, there remains an unmet need for the investigation of its use in treating neonates. The purpose of this review is to provide a summary of current information on the potential therapeutic benefits and clinical applicability of umbilical cord MSCs and UCB cells. Promising preclinical studies have now led to a research movement that is focusing on cell-based therapies for preterm infants.

Original languageEnglish (US)
Pages (from-to)1378-1387
Number of pages10
JournalJournal of Maternal-Fetal and Neonatal Medicine
Volume32
Issue number8
DOIs
StatePublished - Apr 18 2019

Fingerprint

Neonatology
Regenerative Medicine
Umbilical Cord
Mesenchymal Stromal Cells
Premature Infants
Therapeutics
Premature Birth
Embryonic Stem Cells
Cell- and Tissue-Based Therapy
Fetal Blood
Blood Cells
Hospitalization
Bone Marrow
Newborn Infant
Morbidity
Health
Research

Keywords

  • Bronchopulmonary dysplasia
  • hypoxic ischemic encephalopathy
  • mesenchymal stem cells
  • umbilical cord blood

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynecology

Cite this

Upcycling umbilical cords : bridging regenerative medicine with neonatology. / Moreira, Alvaro G; Alayli, Yasmeen; Balgi, Saloni; Winter, Caitlyn; Kahlenberg, Samuel; Mustafa, Shamimunisa B; Hornsby, Peter J.

In: Journal of Maternal-Fetal and Neonatal Medicine, Vol. 32, No. 8, 18.04.2019, p. 1378-1387.

Research output: Contribution to journalReview article

Moreira, Alvaro G ; Alayli, Yasmeen ; Balgi, Saloni ; Winter, Caitlyn ; Kahlenberg, Samuel ; Mustafa, Shamimunisa B ; Hornsby, Peter J. / Upcycling umbilical cords : bridging regenerative medicine with neonatology. In: Journal of Maternal-Fetal and Neonatal Medicine. 2019 ; Vol. 32, No. 8. pp. 1378-1387.
@article{ce41eeaeb25e43edb720925017be9616,
title = "Upcycling umbilical cords: bridging regenerative medicine with neonatology",
abstract = "Preterm birth is a major health concern that affects 10{\%} of all worldwide deliveries. Many preterm infants are discharged from the hospital with morbidities that lead to an increased risk for neurodevelopmental impairment, recurrent hospitalizations, and life-long conditions. Unfortunately, the treatment of these conditions is palliative rather than curative, which calls for novel and innovative strategies. Progress in regenerative medicine has offered therapeutic options for many of these conditions. Specifically, human umbilical cord mesenchymal stem cells (MSCs) and cord blood (UCB) cells have shown promise in treating adult-onset diseases. Unlike bone-marrow and embryonic derived stem cells, umbilical cord-derived cells are easily and humanely obtained, have low immunogenicity, and offer the potential of autologous therapy. While there are several studies to uphold the efficacy of umbilical cord MSCs in adult therapies, there remains an unmet need for the investigation of its use in treating neonates. The purpose of this review is to provide a summary of current information on the potential therapeutic benefits and clinical applicability of umbilical cord MSCs and UCB cells. Promising preclinical studies have now led to a research movement that is focusing on cell-based therapies for preterm infants.",
keywords = "Bronchopulmonary dysplasia, hypoxic ischemic encephalopathy, mesenchymal stem cells, umbilical cord blood",
author = "Moreira, {Alvaro G} and Yasmeen Alayli and Saloni Balgi and Caitlyn Winter and Samuel Kahlenberg and Mustafa, {Shamimunisa B} and Hornsby, {Peter J}",
year = "2019",
month = "4",
day = "18",
doi = "10.1080/14767058.2017.1405387",
language = "English (US)",
volume = "32",
pages = "1378--1387",
journal = "Journal of Maternal-Fetal and Neonatal Medicine",
issn = "1476-7058",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Upcycling umbilical cords

T2 - bridging regenerative medicine with neonatology

AU - Moreira, Alvaro G

AU - Alayli, Yasmeen

AU - Balgi, Saloni

AU - Winter, Caitlyn

AU - Kahlenberg, Samuel

AU - Mustafa, Shamimunisa B

AU - Hornsby, Peter J

PY - 2019/4/18

Y1 - 2019/4/18

N2 - Preterm birth is a major health concern that affects 10% of all worldwide deliveries. Many preterm infants are discharged from the hospital with morbidities that lead to an increased risk for neurodevelopmental impairment, recurrent hospitalizations, and life-long conditions. Unfortunately, the treatment of these conditions is palliative rather than curative, which calls for novel and innovative strategies. Progress in regenerative medicine has offered therapeutic options for many of these conditions. Specifically, human umbilical cord mesenchymal stem cells (MSCs) and cord blood (UCB) cells have shown promise in treating adult-onset diseases. Unlike bone-marrow and embryonic derived stem cells, umbilical cord-derived cells are easily and humanely obtained, have low immunogenicity, and offer the potential of autologous therapy. While there are several studies to uphold the efficacy of umbilical cord MSCs in adult therapies, there remains an unmet need for the investigation of its use in treating neonates. The purpose of this review is to provide a summary of current information on the potential therapeutic benefits and clinical applicability of umbilical cord MSCs and UCB cells. Promising preclinical studies have now led to a research movement that is focusing on cell-based therapies for preterm infants.

AB - Preterm birth is a major health concern that affects 10% of all worldwide deliveries. Many preterm infants are discharged from the hospital with morbidities that lead to an increased risk for neurodevelopmental impairment, recurrent hospitalizations, and life-long conditions. Unfortunately, the treatment of these conditions is palliative rather than curative, which calls for novel and innovative strategies. Progress in regenerative medicine has offered therapeutic options for many of these conditions. Specifically, human umbilical cord mesenchymal stem cells (MSCs) and cord blood (UCB) cells have shown promise in treating adult-onset diseases. Unlike bone-marrow and embryonic derived stem cells, umbilical cord-derived cells are easily and humanely obtained, have low immunogenicity, and offer the potential of autologous therapy. While there are several studies to uphold the efficacy of umbilical cord MSCs in adult therapies, there remains an unmet need for the investigation of its use in treating neonates. The purpose of this review is to provide a summary of current information on the potential therapeutic benefits and clinical applicability of umbilical cord MSCs and UCB cells. Promising preclinical studies have now led to a research movement that is focusing on cell-based therapies for preterm infants.

KW - Bronchopulmonary dysplasia

KW - hypoxic ischemic encephalopathy

KW - mesenchymal stem cells

KW - umbilical cord blood

UR - http://www.scopus.com/inward/record.url?scp=85060283290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060283290&partnerID=8YFLogxK

U2 - 10.1080/14767058.2017.1405387

DO - 10.1080/14767058.2017.1405387

M3 - Review article

C2 - 29132234

AN - SCOPUS:85060283290

VL - 32

SP - 1378

EP - 1387

JO - Journal of Maternal-Fetal and Neonatal Medicine

JF - Journal of Maternal-Fetal and Neonatal Medicine

SN - 1476-7058

IS - 8

ER -